An in vivo study demonstrated that inhibition of PLOD2 reduced tumor growth and enhanced the efficacy of anti-PD-1 therapy, highlighting PLOD2 as a potential novel therapeutic target in UPS immunotherapy [113]. This evidence concerns the gene PLOD2 and undifferentiated pleomorphic sarcoma.